Patient focused research for better outcomes
Bring your clinical trial directly to patients when and where it's convenient for them to reduce patient burden and increase recruitment and retention.
Monitoring strategies based on risk analysis and assesment for more resilient operations.
Everyone is talking about decentralised clinical trials. But how can we leverage what we learnt during 2020 and move forward in a more systematic way to deploy this approach with maximum efficiency and optimum results?Read the whitepaper
ICON invited senior biopharma executives to discuss how decentralised and hybrid clinical trial models can provide increased resilience and to share how their respective organisations are currently or likely to address diversity and inclusion in clinical trials going forward. This summary report outlines how these executives see the opportunity in the developments of 2020, paving the way for continuous improvements into the future.Read the summary report
Engaging patients more fully and making sure decentralised clinical trials are easing rather increasing burden is going to be crucial to using these models in the longer term. Early in 2021, ICON conducted a survey to compare it to one conducted in 2019 to see if the COVID-19 outbreak had changed the sentiment and increased interest in participating in clinical trials remotely.Read the survey results
Bringing clinical trial visits to patients in their homes decreases burden and leads to higher enrollment rates. Explore the benefits and solutions to overcome perceived barriers so that you can provide this as an option on your next trial.Read the whitepaper
Although mHealth devices and sensors are continuing to evolve, and it is now possible to capture a vast array of physiological data, the operationalisation of digital trials is not without challenges. Navigate the shift from traditional trial models to agile, patient-centric processes driven by digital health technologies.Read the whitepaper
During COVID-19 the levels of remote monitoring increased due to site closures and safety reasons. Now is the time to learn from that experience and review whether a hybrid model of remote monitoring and centralised monitoring is the way forward for some trials. Learn best practices in analysing and assessing risk in clinical monitoring and how to remain agile adapting to environmental conditions and therapeutic focus.Read the whitepaper
Bringing the trial to the patient:
Understand how to implement wearable devices and harness digital endpoints in clinical trials:
Understanding the regulatory and legal aspects behind the technology applied in decentralised clinical trials.
ICON's E.B. McLindon speaks at Decentralized Clinical Trials digital week. Gain insights and perspectives on design studies, to improve patient engagement and meeting study endpoints.
The COVID-19 outbreak has driven the desire for more resilient clinical trials. The deployment of remote clinical monitoring is proving its value in helping to keep trials going at a time when site management is particularly challenging.
The FDA guidance on clinical trials during COVID-19 advised sponsors to evaluate alternative methods for safety assessments to protect patients, where necessary and feasible.
The collection of real-time data in a home setting can give sponsors and trial managers greater visibility and assurance around GCP and protocol compliance.
How to best incorporate digital endpoints at every stage of clinical research.
Please visit ICON's Preference Centre and select 'Decentralised & Hybrid Clinical Trials' under 'Patient Centricity' to receive new insights on decentralised & hybrid clinical trials.Receive new insights
Harpreet Gill, Vice President, Decentralised Clinical Trials at ICON reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years in this article in PharmaTimes.
As DCT adoption increases, Harpreet Gill looks at how sponsors and CROs must mind the risk of adding patient burden while designing decentralised trials.
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. Laney Preheim outlines how they can best be implemented.
Dr. Isaac R. Rodriguez-Chavez discusses the technology advancements that are making decentralised trial growth possible.
Dr. Isaac R. Rodriguez-Chavez discusses the various factors behind the DCT format's rapid rise and likely longevity in the drug development arena.
Dr. Isaac R. Rodriguez-Chavez outlines the key considerations when developing digital health technologies.
Dr. Isaac R. Rodriguez-Chavez offers his insights on the use of innovative digital health technologies and digital ecosystems to support decentralised clinical trials.
Matt Harrington explores how the use of digital platforms and associated services can contribute to more adaptable, accessible and efficient clinical trials.
Emily Mitchell discusses the importance of considering the target patient population when designing and deploying a decentralised clinical trial.
Emily Mitchell and Kathleen Mandziuk discuss how study data has progressed in recent years and how trial teams can keep up effectively with proper data management.
A snapshot from the J.P. Morgan Healthcare Conference 2022.
An interview with Jodie Huddleston on the use of hybrid and decentralised models as viable solutions in clinical trial design.
Emily Mitchell and Christina Dinger run through some of the most important elements of collating and organising data during clinical trials.
Isaac Rodriguez-Chavez discusses the impact decentralised trials have had on the industry, and how that transformation is likely to continue.
In this video interview, Kim Boericke, President, Commercialization and Outcomes Services, discusses what is driving a great focus and intensity on outcomes in clinical trials, trends coming in 2022, and the use of real-world data and the rare disease space.
In this article, our experts discuss the challenges and change management approaches that ICON faced during the COVID-19 pandemic, and how we overcame them through the use of decentralised and hybrid clinical trials.
This three part video series examines some of the factors that should be considered to ensure that clinical trial data captured via wearable devices, is monitored expeditiously and effectively.
Isaac R Rodriguez-Chavez contributes to the DPHARM Autumn 2021 newsletter, discussing the use of digital health to maximise efficiencies in decentralised clinical trials.
ICON's Kent Thoelke discusses today’s key trends for CROs, including the increasing adoption of decentralised clinical trials (DCTs) and the growing use of remote monitoring to collect data.
The research industry has changed in the past year, and decentralised models are helping to improve patient outcomes and bring treatments to market faster (page 12).
A discussion around the key components of decentralised trials and steps of deployment.
Wearables and other mobile technologies are increasingly recognised as drivers of democratisation and diversification in clinical trials.
COVID-19 may be the inflection point that tips clinical trial practices into the digital age.
Digital health has been a hot topic for many years, but it has taken the pandemic to really highlight its value across many areas of the pharma and biotech industries.
Choosing the best option for your clinical trial.
Wearables are improving the clinical trial experience for patients and satisfying the need to collect data for real-world use studies.
Starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
Reducing the burden that clinical trial participation places on patients can help to keep patients engaged in clinical research.
Seven steps to closing the gap between rhetoric and reality in patient-centricity.
Exploring the patient perspective from different angles.
Steps to implement security into mHealth development.
Patient engagement is permeating all spheres of the healthcare ecosystem.
Revolutionising clinical trials with wearables and digital endpoints.
Project teams need to be challenged constantly to justify the study procedures and eligibility criteria they are proposing.
How can pharma improve the patient centricity of its trials during COVID-19 and beyond?
Decentralised and hybrid trials bring a wide range of benefits to the patient and the sponsor. Find out more about the range of decentralised and hybrid trials services available from ICON.Read more about ICON's services